Original Research Paper

The preventive effect of *Brassica napus* L. oil on pathophysiological changes of respiratory system in experimental asthmatic rat

Mehdi Kabiri rad¹, Ali Neamati¹*, Mohammad Hossein Boskabady², Naser Mahdavi-Shahri¹, Maryam Mahmoudabady²

Abstract

**Objective**: Asthma is an airway complex disease defined by reversible airway narrowing and obstruction, chronic airway inflammation, airway hyperresponsiveness, and tissue remodeling. The purpose of this study was to determine the effect of *Brassica napus* L. (*B. napus*) on airway pathologic changes in a rat model of asthma.

**Materials and Methods**: Twenty-four rats were divided into 4 groups: control, asthmatic, asthmatic treated with 0.5 mg/kg *B. napus* oil, and asthmatic treated with 0.75 mg/kg *B. napus* oil. To induce the experimental asthma, rats in groups 2, 3, and 4 received an i.p. injection of ovalbumin and aerosolized ovalbumin. Simultaneously, rats in groups 3 and 4 received *B. napus* oil daily by gavage. After 31 days, in all groups, thoracotomy was done and lung tissue samples were taken. For pathological evaluation, microscopic slides were prepared. The eosinophil numbers in the submucosal layer and thicknesses of smooth muscle layer of bronchioles were detected.

**Results**: Eosinophil numbers in the submucosal layer, as well as smooth muscle layer thicknesses were significantly lower in the rat group treated with 0.75 mg/kg *B. napus* oil as compared with asthmatic group (p<0.01, p<0.05).

**Conclusion**: *B. napus* could be useful as adjuvant therapy in rat model of asthma. This effect was probably related to its antioxidants components that reduce the levels of inflammatory mediators such as leukotrienes, IL-4, IL-5, and IL-13.

**Keywords**: Airway Remodeling, Asthma, *Brassica napus*, Eozinophil, Inflammation, Rat, Sensitization

1- Department of Biology, Faculty of Science, Mashhad Branch, Islamic Azad University, Mashhad, I. R. Iran
2- Applied Physiology Research Centre and Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, I. R. Iran

*Corresponding author*: Tel: +985118435050
E-mail: aneamati@mshdiau.ac.ir
Introduction

Asthma is an airway complex disease with reversible obstruction, airway hyperresponsiveness, inflammation, and remodeling of respiratory airways. The model includes structural changes of bronchial tree that can affect all layers. These changes include: epithelial metaplasia, hyperplasia of goblet cells and increase of mucus secretion, subepithelial fibrosis, increased smooth muscle mass due to hyperplasia and hypertrophy of cells, and increase in the number and diameter of the vessels. During the process of inflammation, migration of inflammatory cells, particularly eosinophils and mast cells to the submucosal and epithelium increase the number of these cells in bronchoalveolar lavage fluid (Martin and Tamaoka, 2006; Scheerens et al., 2002; Szelenyi, 2000).

Among the inflammatory cells implicated in asthma, it is shown that activation of T helper 2 (Th2) causes airway inflammation and airway hyperresponsiveness. Activation of Th2 cells produces several cytokines such as interleukin (IL)-4, IL-13, IL-5, and IL-10. IL-4 and IL-13 elicit IgE production, IL-5 promotes eosinophil production in the bone marrow and IL-10 promotes B-cell differentiation into plasma cells (Cohn et al., 2004; Randolph et al., 1999).

Previous studies reported increased production of oxygen radicals and decreased antioxidant reserves such as glutathione, glutathione peroxidase, superoxide dismutase, vitamin C, and vitamin E in plasma and lavage fluid of asthmatic subjects. With increasing oxygen radicals, peroxidation of proteins, lipids, and nucleic acids a severe increase in responsiveness, secretion, and permeability of blood vessels occurs. In addition, free radicals activate inflammatory factors which result in exacerbation of allergic reactions (Murdoch and Lloyd, 2010; Charavaryamath, 2005).

In this study the effects of *B. napus* L. (referred to as ‘canola’), on pathological changes of respiratory airways in a model of experimental asthma in rats were investigated. *B. napus* contains important antioxidants and omega-3 fatty acids, tocopherols (vitamin E), especially alpha- and gamma-tocopherol, polyphenols, and carotenoids such as carotene and xanthophylls. It is supposed to reduce inflammation and inflammatory mediators so that asthma symptoms alleviate (Elhiti et al., 2012; Fritsche et al., 2012; Horie et al., 2010; Xue et al., 2009).

Materials and Methods

Twenty-four male and female Wistar rats of 3 month old, weighing approximately 200–250 g were used in the present study. Animals were housed in PVC cages under 12:12 light/dark cycle at 20±2 °C and were fed ad libitum with standard rat chow and tap water.

Animal sensitization and animal groups

Animals were sensitized to OA according to the method described previously (Schuster et al., 2000). Briefly, rats were sensitized to 1 mg OA (Sigma Chemical Ltd, UK) and 200 mg Al(OH)₃ dissolved in 1 ml saline i.p. One week later they were given 1 mg OA and 200 mg Al(OH)₃ dissolved in 1 ml saline i.p. as a booster dose. From day 14, sensitized animals were exposed to an aerosol of 4% OA for 18±1 days, 5 min daily. The aerosol was administered in a closed cylinder, measured 19 cm diameter and 16 cm high and 3 liter volume. Control animals were treated similarly but saline was used instead of OA solution. The study was approved by the ethical committee of the Mashhad Branch, Islamic Azad University, Mashhad, Iran.

The animals were divided into 4 groups (n=6 for each group) as follow:
1- "Control" group.
2- "Asthma" group; an animal model of asthma.
3- Group "Asthma+T 0.5" which was treated with 0.5 mg/kg *B. napus* oil for
31 days after sensitization.

4- Group "Asthma+T 0.75" which was treated with 0.75 mg/kg *B. napus* oil for 31 days after sensitization. The net oil of *B. napus* was provided from Ladan Company, Iran.

**Tissue preparation and histopathological analysis**

At the end of the protocol, the animals were killed by i.p. administration of ketamine/xylazine. Lungs were fixed in formalin and embedded in paraffin. Tissue sections (5 µm) were stained with hematoxylin-eosin and examined under light microscopy to evaluate the eosinophil numbers in the submucosal layer and thicknesses of smooth muscle layer of bronchioles.

The thicknesses of smooth muscle layer were measured in 8 points of 2-3 bronchiole ducts and the mean was reported. The number of eosinophils in submucosal layer of each bronchiole duct was counted and to determine it in 100 µm of submucosal layer the following formula was used:

\[
\text{Bronchiole duct circumference} = \pi \times \text{bronchiole duct diameter} \times \frac{\text{Number of eosinophils in 100 µm of submucosal layer}}{\text{Number of eosinophils in submucosal layer}}
\]

**Statistical analysis**

All data were expressed as mean±SEM. Comparisons were performed using one-way ANOVA with SPSS software. *P*-values less than 0.05 were considered to be statistically significant.

**Results**

The number of eosinophils in submucosal layer of bronchioles in asthmatic group of rats was significantly increased compared with control group. This parameter in the groups treated with *B. napus* oil was decreased compared with asthmatic group (Figure 1). The reduction in "Asthma+T 0.75" group was significant (*p*<0.01, Figure 2).

The thickness of smooth muscle layer of bronchioles in asthmatic group of rats was significantly increased compared with control group. This index in the groups treated with *B. napus* oil was decreased compared with asthmatic group (Figure 3). The reduction in "Asthma+T 0.75" group was significant (*p*<0.05, Figure 4).
The effect of B. napus oil on asthma

Figure 1. Hematoxylin-eosin staining (magnification ×400). Eosinophil cells (black arrows) in 100 µm of submucosal layer of bronchioles in (a) Control group (b) Asthmatic group (c) "Asthma+T 0.5" (d) "Asthma+T 0.75".

Figure 2. Number of eosinophils in 100 µm of submucosal layer of bronchioles in different groups of study. Data are expressed as mean±SEM. (n = 6). **p<0.01, versus Asthma group. ***p< 0.001, versus Control group.
Figure 3. Hematoxylin-eosin staining (magnification ×400). Smooth muscle layer thickness (black arrows) of bronchioles in (a) Control group (b) Asthmatic group (c) "Asthma+T 0.5" (d) "Asthma+T 0.75".

Figure 4. Thickness of smooth muscle layer of bronchioles in different groups of study. Data are expressed as mean±SEM. (n = 6). *p<0.05 versus Asthma group, ***p<0.001 versus Control group.

Discussion
The results of this study showed the number of eosinophils in 100 µm of submucosal layer as well as the thickness of smooth muscle layer of bronchioles in groups treated with B. napus oil was less than asthmatic group.
This protective effect of B. napus oil was more visible in higher dose. Since asthma is a common inflammatory disease
The effect of B. napus oil on asthma

of respiratory system (Zhang et al., 2011; Cohn et al., 2004; Randolph et al., 1999), anti-inflammatory drugs are the mainstay therapy in this condition (Hakim et al., 2012; Higashi et al., 2012).

There are different documents which show anti-oxidant and anti-inflammatory properties of B. napus (Elhiti et al., 2012; Fritsche et al., 2012; Horie et al., 2010; Xue et al., 2009). As the present study showed, B. napus reduced the eosinophil numbers in the submucosal layer, as well as smooth muscle layer thicknesses of bronchioles in sensitized rats so it can confirm the anti-inflammatory effect of this plant. According to investigations, the most important inflammatory mediators implicated in the pathogenesis of asthma include:

1. IL-3: involves in the production of IgE and initiating of inflammation, increases the thickness of smooth muscle layer by smooth muscle cell hyperplasia (Ma et al., 2007).
2. IL-4: involves in the production of IgE and initiation of inflammation (Murdoch and Lloyd, 2010).
3. IL-5: increases both production of eosinophils in the bone marrow and activation of them. Activated eosinophils release lipid mediators including leukotrienes, prostaglandins, and platelet-activating factors similar to mast cells and basophils (Halwani et al., 2010).
4. Leukotrienes: cause bronchospasm, airway wall edema, excess mucus secretion, increase vascular permeability, and migration of inflammatory cells (Simopoulos, 2009).

Moreover, it was shown that antioxidants such as omega-3, vitamin E, a-lipoic acid, and mepacrine reduce leukotrienes, IL-4, and IL-13. As Broughton showed in 1997 with a population of asthmatics, omega-3 fatty acids decreased leukotrienes production (Broughton et al., 1997). This reduction was mediated by blocking of arachidonic acid metabolism (Simopoulos, 2009). In 1988, Hashimoto and colleagues demonstrated increased linolenate (omega-3) to linoleate (omega-6) ratio in diet decreased leukotrienes (Hashimoto et al., 1988). In 2002, Li-weber and colleagues showed that vitamin E inhibited IL-4 gene expression in peripheral T cells (Li-Weber et al., 2002).

One study reported that γ-tocopherol reduced inflammation by inhibiting inflammatory mediators such as prostaglandin and leukotrienes and reducing tumor necrosis factor (TNF) (Jiang and Amesb, 2003). Ram and colleagues in 2008 showed in a mouse-model of asthma that mepacrine (as antioxidant) decreased inflammation and airway hyperresponsiveness and reduced significantly the amount of IL-4, IL-5, IL-13, IgE, leakage of inflammatory cells, and the number of eosinophils in bronchoalveolar lavage fluid (Ram et al., 2008). In 2011, Boskabady and colleagues demonstrated that in sulfur mustard exposed guinea pigs, vitamin E significantly reduced response reaction, the amount of white blood cells (WBC) particularly eosinophils, and IL-4 (Boskabady et al., 2011).

Above mentioned studies show the effects of antioxidants on inflammatory mediators and confirm our results about eosinophils. Moreover, omega-3 and vitamin E prevent oxidation of fatty acids in membrane lipids thus have anti-inflammatory effects by stabilizing cell membranes (Sagols and Priymenko, 2011).

In the other hand, vitamin E regulates T lymphocyte activity and inhibits the production of IgE (Park et al., 2010).

As B. napus oil contains high levels of antioxidants such as omega-3 and vitamin E, it can reduce necrosis and migration of eosinophils as well as inhibits smooth muscle cell hyperplasia in the walls of respiratory tract by decreasing the amount of leukotrienes, IL-13, and IL-4. B. napus oil improves some symptoms of experimental asthma in rats. These effects are likely due to its antioxidants including omega-3, vitamin E (tocopherol),
polyphenols, and carotenoids which reduce the mediators of inflammation and inflammatory cytokines such as IL-4, IL-13, and leukotrienes.

In conclusion the results of the present study suggest *B. napus* could be useful as adjuvant therapy in rat model of asthma. This effect was probably related to its anti-inflammatory and antioxidants components.

**Acknowledgments**

This paper is a part of a M.Sc. thesis that was conducted in Islamic Azad University, Mashhad Branch. The authors would like to thank all personnel of Department of Biology IAUM who helped to carry out this research.

**Conflict of interest**

There is not any conflict of interest in this study.

**References**

Boskabady MH, Amery S, Vahedi N, Khakzad MR. 2011. The effect of vitamin E on tracheal responsiveness and lung inflammation in sulfur mustard exposed guinea pigs. Inhal Toxicol, 23: 157-165.

Broughton KS, Johnson CS, Pace BK, Liebman M, Kleppinger KM. 1997. Reduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leukotriene production. Am J Clin Nutr, 65: 1011-1017.

Charavaryamath C, Janardhan KS, Townsend HG, Willson P, Singh B. 2005. Multiple exposures to swine barn air induce lung inflammation and airway hyper-responsiveness. Respir Res, 6:50.

Cohn L, Elias JA, Chupp GL. 2004. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol, 22: 789-815.

Elhiti M, Yang C, Belmonte MF, Gulden RH, Stasolla C. 2012. Transcriptional changes of antioxidant responses, hormone signalling and developmental processes evoked by the *Brassica napus* SHOOTMERISTEMLESS during in vitro embryogenesis. Plant Physiol Biochem, 58: 297-311.

Fritsche S, Wang X, Li J, Stich B, Kopisch-Obuch FJ, Endrigkeit J, Leckband G, Dreyer F, Friedt W, Meng J, Jung C. 2012. A Candidate Gene-Based Association Study of Tocopherol Content and Composition in Rapeseed (*Brassica napus*). Front Plant Sci, 3: 129.

Hakim A, Adcock IM, Usmani OS. 2012. Corticosteroid resistance and novel anti-inflammatory therapies in chronic obstructive pulmonary disease: current evidence and future direction. Drugs, 72: 1299-312.

Halwani R, Al-Muhsen S, Hamid Q. 2010. Airway remodeling in asthma. Current Curr Opin Pharmacol, 10: 236-245.

Hashimoto A, Katagiri M, Torii S, Dainaka J, Ichikawa A, Okuyama H.1988. Effect of dietary α-linolenate/linoleate balance on leukotriene production and histamine release in rats. Prostaglandins, 36: 3-16.

Higashi A, Kumlin M, Higashi N, Daham K, Gaber F, Lindeberg A, James A, Skedinger M, Delin I, Gyllfors P, Dahlén SE, Dahlén B. 2012. Challenge of isolated sputum cells supports in vivo origin of intolerance reaction to aspirin/non-steroidal anti-inflammatory drugs in asthma. Int Arch Allergy Immunol, 158: 299-306.

Horie S, Okuda C, Yamashita T, Watanabe K, Kuramochi K, Hosokawa M, Takeuchi T, Kakuda M, Miyashita K, Sugawara F, Yoshida H, Mizushima Y. 2010. Purified canola lutein selectively inhibits specific isoforms of mammalian DNA polymerases and reduces inflammatory response. Lipids, 45:713-721.

Jiang Q, Amesb N. 2003. γ-Tocopherol, but not α-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J, 17: 816-822.

Li-Weber M, Giaisi M, Treiber MK, Krammer PH. 2002. Vitamin E inhibits IL-4 gene expression in peripheral blood T cells. Eur J Immunol, 32: 2401-2408.

Ma Y, Ma AG, Peng Z. 2007. A potential immunotherapy approach: Mucosal immunization with an IL-13 peptide-based virus-like particle vaccine in a mouse asthma model. Vaccine, 25: 8091-8099.

Martin JG, Tamaoka M. 2006. Rat models of asthma and chronic obstructive lung disease. Pulm Pharmacol Ther, 19: 377-385.
The effect of *B. napus* oil on asthma

Murdoch JR, Lloyd CM. 2010. Chronic inflammation and asthma. Mutat Res, 690: 24-39.

Park HS, Kim SR, Kim JO, Lee YC. 2010. The Roles of Phytochemicals in Bronchial Asthma. Molecules, 15: 6810-6834.

Ram A, Mabalirajan U, Singh SK, Singh VP, Ghosh B. 2008. Mepacrine alleviates airway hyperresponsiveness and airway inflammation in a mouse model of asthma. Int Immunopharmacol, 8: 893-899.

Randolph DA, Stephens R, Carruthers CJL. 1999. Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inflammation. J Clin Invest, 104: 1021-1029.

Sagols E, Priymenko N. 2011. Oxidative Stress in Dog with Heart Failure: The Role of Dietary Fatty Acids and Antioxidants. Vet Med Int, 6:180206.

Scheerens J, van Gessel SBE, Nijkamp FP, Folkerts G. 2002. Eotaxin protein levels and airway pathology in a mouse model for allergic asthma. Eur J Pharmacol, 453: 111-117.

Schuster M, Tschernig T, Krug N, Pabst R. 2000. Lymphocytes migrate from the blood into the bronchoalveolar lavage and lung parenchyma in the asthma model of the brown Norway rat. Am J Respir Crit Care Med; 161: 558-566.

Simopoulos AP. 2009. The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases. 2008. Exp Biol Med (Maywood), 233: 674-688.

Szelenyi I. 2000. Animal models of bronchial asthma. Inflamm. Res, 49: 639-654.

Von Hertzen LC, Haahetela T. 2000. could the risk of asthma and atopy is reduced by a vaccine that induces a strong T-helper type 1 response? (See comments). Am J Respir Cell Mol Biol, 22: 139-142.

Xue Z, Yu W, Liu Z, Wu M, Kou X, Wang J. 2009. Preparation and antioxidative properties of a rapeseed (Brassica napus) protein hydrolysate and three peptide fractions. J Agric Food Chem, 57:5287-93.

Zhang Y, Zhang J, Tian C, Xiao Y, He C, Li X, Bogati A, Huang J, Fan H. 2011. The -308 G/A polymorphism in TNF-α gene is associated with asthma risk: an update by meta-analysis. J Clin Immunol, 31: 174-85.